STOCK TITAN

Cellectis S.A. (CLLS) SEC Filings

CLLS NASDAQ

Cellectis S.A. filings document a foreign private issuer focused on clinical-stage gene-edited cell and gene therapies. Recent Form 6-K reports furnish press-release exhibits covering financial-results announcements, business updates, research presentations, and clinical program disclosures for the company's allogeneic CAR T and gene-editing platforms.

The filing record also reflects disclosure topics tied to Cellectis' Nasdaq and Euronext Growth listings, including its Form 20-F reporting status, pipeline updates for lasme-cel, eti-cel and cema-cel, license and collaboration references involving Servier, Allogene and AstraZeneca, and formal communications about strategy, research data and corporate developments.

Rhea-AI Summary

Cellectis S.A. (CLLS) reported Q3 2026 total revenues and other income of $5.439 million, versus $37.164 million a year earlier, and a net loss of $61.474 million, versus net income of $0.589 million. For the nine months ended September 30, 2026, revenues and other income were $19.9 million, versus $67.4 million, and net loss attributable to shareholders was $101.1 million, versus $41.3 million. R&D expenses were $108.8 million, including $26.6 million in one-off impairment losses tied to the strategic transformation.

Cash, cash equivalents, restricted cash and fixed-term deposits totaled $149 million as of September 30, 2026; Cellectis believes its existing cash and cash equivalents, together with fixed-term bank deposits, will fund operations into H2 2028 when realignment is fully implemented as planned. .HEAL-101 showed up to 70% APOC3 editing and a 76% triglyceride reduction in mouse models. China Phase 1 IIT initiation is on track, with preliminary data expected in H2 2027. .HEAL-201 reduced plasma PCSK9 by more than 90% in a humanized liver mouse model; preliminary clinical data are expected in H1 2028. Cellectis is discontinuing lasme-cel and eti-cel; enrollment has stopped and site close-out is underway. Global headcount is expected to fall by up to 70% over 2026 and 2027, subject to French works council consultation and applicable French and U.S. labor laws.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.28%
Tags
current report
-
Rhea-AI Summary

Cellectis S.A. (CLLS) reported revenue of $14.8 million for the nine months ended September 30, 2026, compared with $62.6 million in 2025, and a net loss of $101.1 million versus $41.3 million. Operating cash used was $45.9 million, compared with $29.0 million a year earlier. The company recorded a $26.8 million impairment loss on assets as part of its strategic transformation. In the third quarter, revenue was $3.8 million versus $35.2 million, and net loss was $61.5 million versus net income of $0.6 million.

On September 14, 2026, Cellectis announced a strategic transformation to focus on in vivo gene editing for chronic diseases, including .HEAL-101 and .HEAL-201. It decided to exit development of lasme-cel and eti-cel while seeking strategic partnering opportunities. Organizational and resource realignment is subject to completion of the relevant French works council consultation process and applicable French and U.S. labor law requirements. As of September 30, 2026, cash and cash equivalents were $28.2 million and fixed-term deposits were $118.3 million. The company believes these resources will fund operations for at least 12 months following board approval on November 12, 2026; this estimate is forward-looking and subject to risks and uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.28%
Tags
current report
-
Rhea-AI Summary

Cellectis S.A. will report third-quarter 2026 financial results for the quarter ended September 30, 2026, on November 12, 2026, after the U.S. market close. An investor conference call and webcast will follow on November 13 at 8:00 a.m. ET / 2:00 p.m. CET, covering the results and a business-activities update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
current report
Rhea-AI Summary

Cellectis S.A. (CLLS) shares were sold by CDC Croissance S.A. in open-market transactions on eight dates: September 15, 2026, 284,444 shares at a weighted average EUR1.36; September 16, 70,671 at EUR1.19; September 17, 94,885 at EUR1.23; October 19, 2026, 111,425 at EUR0.96; October 20, 158,575 at EUR0.93; October 26, 31,734 at EUR0.94; October 27, 179,581 at EUR0.93; and October 28, 88,685 at EUR1.07. Each day’s sales comprised multiple transactions at varying prices.

Bpifrance Participations directly held 5,873,247 ordinary shares, reported as approximately 8.1% of outstanding shares under the U.S. calculation, and had 9,559,534 related voting rights, approximately 10.0%. The percentages use 72,732,781 outstanding shares and 95,563,044 outstanding voting rights as of September 30, 2026. Under French-law counts, the corresponding totals were 100,732,781 shares and 105,563,044 voting rights; Bpifrance Participations’ percentages were approximately 5.8% and 9.1%, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
ownership
-
Rhea-AI Summary

Cellectis S.A. announced expanded preclinical data for .HEAL-101, its in vivo base-editing candidate targeting APOC3 for severe hypertriglyceridemia, at ESGCT 2026. In a human hepatic cell line, the candidate produced approximately 90% mean APOC3 editing, without production of DNA double-strand breaks at the target site. In a humanized-liver mouse model, mean human APOC3 editing was approximately 65%, reaching up to 70%.

In a hypertriglyceridemic human APOC3 transgenic mouse model, .HEAL-101 reduced APOC3 by 67% ± 12% and triglycerides by 75% ± 11% (mean ± standard deviation). Editing was detected in the liver, with no significant activity in other tissues analyzed. Cellectis plans to initiate a Phase 1 investigator-initiated trial in China; preliminary clinical data are expected in the second half of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.00%
Tags
current report
-
Rhea-AI Summary

Cellectis S.A. (CLLS) announced a strategic transformation to focus on becoming an in vivo gene editing company, centered on two lead programs, .HEAL-101 for severe hypertriglyceridemia and .HEAL-201 for severe hypercholesterolemia. Both are supported by promising preclinical proof-of-concept and are planned to enter Phase 1 investigator-initiated trials in China, with preliminary data expected in H2 2027 for .HEAL-101 and H1 2028 for .HEAL-201.

The company will exit internal development of its allogeneic CAR-T candidates lasme-cel and eti-cel, citing a materially changed competitive and clinical landscape, and will seek partners for these assets while continuing its existing cell therapy collaborations with AstraZeneca, Allogene, Servier and Iovance. Cellectis plans to realign its operating model, including organizational changes, with the goal of extending its cash runway into H2 2028, excluding any impact from potential partnering of lasme-cel and/or eti-cel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.97%
Tags
current report
Rhea-AI Summary

Cellectis S.A. (CLLS), a clinical-stage biotechnology company focused on gene-edited cell and gene therapies, announced it will host a conference call and webcast on September 14, 2026 to provide a business update. The company will hold an English-language call at 8:00 a.m. ET / 2:00 p.m. CET, followed by a French-language call at 9:00 a.m. ET / 3:00 p.m. CET. Both events will be accessible via webcast and telephone, with a replay available on the company’s website.

Cellectis develops allogeneic CAR T immunotherapies and other gene therapies using its in-house gene-editing and manufacturing platform, with headquarters in Paris and additional locations in New York and Raleigh, NC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.97%
Tags
current report
-
Rhea-AI Summary

Cellectis S.A. (CLLS) filed an amended Form 6-K mainly to add iXBRL formatting, while reaffirming its unaudited results for the six months ended June 30, 2026. Revenue fell to $11.0 million from $27.4 million, largely due to lower activity under AstraZeneca collaboration research plans, while other income rose modestly from higher research tax credits.

Research and development expenses increased to $52.2 million and selling, general and administrative expenses to $11.3 million, driving an operating loss of $48.7 million versus $23.8 million a year earlier. A swing to a $9.2 million net financial gain from an $18.1 million loss, helped by fair value gains on EIB warrants and lower FX losses, narrowed the net loss slightly to $39.6 million ($0.39 per share). Cash and cash equivalents were $35.6 million and current financial assets (fixed-term deposits) $131.3 million, and the company states this liquidity should fund operations for at least 12 months on a going-concern basis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.97%
Tags
current report
-
Rhea-AI Summary

Cellectis S.A. (CLLS), a clinical-stage gene-editing biotechnology company, reports that its management will participate in several upcoming healthcare investor conferences in the U.S. and Europe from September through November 2026. Events include conferences hosted by Wells Fargo, Baird, Barclays, Stifel and Jefferies in Boston, New York and London.

Cellectis’ team will be available for investor meetings at these events, coordinated either through conference organizers or the company’s Investor Relations. Any available webcasts of presentations will be posted in the events and webcasts section of Cellectis’ investor website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
current report
Rhea-AI Summary

Cellectis reported second-quarter and first-half 2026 results while advancing its allogeneic CAR‑T pipeline. Lasme‑cel in r/r B‑ALL received FDA RMAT designation based on Phase 1 BALLI‑01 data showing a 100% overall response rate (7/7) and 57% CR/CRi in the target Phase 2 population with a manageable safety profile; a pivotal Phase 2 interim analysis is expected in Q4 2026. Eti‑cel in r/r NHL showed an 88% ORR and 63% CR rate in an optimal dose cohort, with full Phase 1 data planned in Q4 2026.

For the six months ended June 30, 2026, revenues and other income were $14.5 million versus $30.2 million a year earlier, and net loss attributable to shareholders was $39.6 million (adjusted net loss $35.6 million). Cash, cash equivalents and fixed‑term deposits totaled $169 million as of June 30, 2026, which the company believes will fund operations into Q4 2027. R&D expenses rose to $52.2 million, and net financial result swung to a $9.2 million gain from an $18.1 million loss.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
current report

FAQ

How many Cellectis S.A. (CLLS) SEC filings are available on StockTitan?

StockTitan tracks 46 SEC filings for Cellectis S.A. (CLLS), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Cellectis S.A. (CLLS)?

The most recent SEC filing for Cellectis S.A. (CLLS) was filed on November 13, 2026.